Over 15 years of clinical trial experience
Founded in 1999, Profil Germany has grown to become a unique full-service CRO with an excellent record for professional conduct and scientific expertise in clinical research on diabetes and other metabolic diseases.
The Profil Institut für Stoffwechselforschung GmbH (in English Profil Institute for Metabolic Research), began life as a spin-off of an academic study group at the Department of Metabolic Diseases and Nutrition at the University of Düsseldorf
. Our founders wished to create a dedicated CRO that would address the challenges of diabetes and obesity research and treatment. The company’s achievements are testament to that vision.
Over the years, we have implemented numerous sophisticated methods for pharmacodynamic characterization
of the effects of compounds in early phase trials, and we have been involved in the development of all the currently available major anti-diabetic compounds. Our key competence is the performance of glucose clamp studies, often combined with isotope dilution techniques and muscle or fat biopsies.
Full-service support for clinical trials
Profil is a full-service CRO certified according to ISO 9001:2008 and 13485. We can boast a vast patient database, with over 27,000 people, a dedicated regulatory department, a fully GMP-certified pharmacy and two in-house clinics: Profil Neuss and Profil Mainz. Between them, those clinics have 80 beds, allowing us the capacity to reliably perform clinical studies within agreed timelines.
In addition to excellent facilities, we provide a unique combination of regulatory and scientific expertise to support clinical trial goals. Our team has over 350 members, including 25 physicians and 2 people with master’s degrees in drug regulatory affairs, and our scientific experts are internationally renowned for their contributions in the fields of diabetes, pharmacology, obesity, prediabetes, cardiology, nutrition, and medical technology. This team has to its name over 360 peer-reviewed publications and a significant presence at international diabetes-focused conferences.